Vaxcyte, Inc.

http://investors.vaxcyte.com

Vaxcyte, Inc. is a clinical-stage vaccine innovation company dedicated to engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. Headquartered in San Carlos, California, the company focuses on developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

The company's pipeline includes lead candidates VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV), and VAX-24, a 24-valent PCV, both being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31 is advancing to a Phase 3 adult clinical program and is also being evaluated in a Phase 2 infant clinical program, while VAX-24 is in a Phase 2 infant clinical program. Vaxcyte also has early-stage programs targeting Group A Strep (VAX-A1) and Shigella (VAX-GI), as well as a third-generation PCV candidate, VAX-XL. The company leverages its proprietary cell-free protein synthesis platform, XpressCF™, and advanced chemistry to produce complex proteins and antigens for its vaccine candidates.

Led by CEO Grant Pickering, Vaxcyte has recently completed enrollment in its OPUS-1 and OPUS-2 Phase 3 clinical trials for VAX-31, evaluating its efficacy against IPD and pneumonia in adults. Positive Phase 1/2 adult data for VAX-31 has been published in The Lancet Infectious Diseases, highlighting its potential. The company also reported VAX-24 infant study results in March 2025, with VAX-31 infant Phase 2 data anticipated in mid-2026. In May 2025, Vaxcyte strengthened its Board of Directors with the appointment of Dr. Olivier Brandicourt, former CEO of Sanofi. Vaxcyte maintains a strong financial position, with approximately $2.82 billion in cash and investments as of June 30, 2025.

Latest updates

Vaxcyte to Detail Pipeline Progress at Needham Healthcare Conference

Event summary

  • Vaxcyte management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026.
  • The conference webcast will be available live and for replay for approximately 30 days.
  • Vaxcyte is developing VAX-31 and VAX-24, pneumococcal conjugate vaccine candidates with broader coverage than existing options.
  • The company utilizes XpressCF®, a cell-free protein synthesis platform licensed from Sutro Biopharma, to accelerate vaccine development.

The big picture

Vaxcyte’s focus on expanding pneumococcal vaccine coverage addresses a significant unmet medical need, particularly given rising antibiotic resistance. The company's reliance on a licensed technology platform, XpressCF®, represents a bet on accelerated development, but also introduces a potential point of vulnerability. The Needham conference provides a key opportunity for Vaxcyte to articulate its progress and strategy to investors.

What we're watching

Clinical Trial
The success of the OPUS Phase 3 adult clinical program for VAX-31 will be critical for Vaxcyte's near-term revenue projections and market positioning, and any setbacks could significantly impact valuation.
Technology Risk
The reliance on the XpressCF® platform from Sutro Biopharma introduces a dependency that could be impacted by Sutro's own operational challenges or strategic shifts.
Competitive Landscape
The conference presentation will likely reveal more about Vaxcyte's differentiation strategy against competitors developing next-generation pneumococcal vaccines, and the effectiveness of that strategy will determine its long-term market share.

Vaxcyte Advances Pneumococcal Vaccine Candidate with Phase 3 Enrollment Complete

Event summary

  • Vaxcyte has completed enrollment for Phase 3 trials (OPUS-1 and OPUS-2) of its 31-valent pneumococcal conjugate vaccine (VAX-31) for adults.
  • OPUS-1 will compare VAX-31 to existing standard-of-care vaccines (Capvaxive® and Prevnar 20®) for safety, tolerability, and immunogenicity; topline data expected in Q4 2026.
  • OPUS-2 will evaluate concomitant administration of VAX-31 and a seasonal influenza vaccine, with results expected in H1 2027.
  • The trials were designed in consultation with the FDA and aim to support a Biologics License Application (BLA) submission.

The big picture

The pneumococcal vaccine market is dominated by Pfizer and Merck, and Vaxcyte’s VAX-31 represents a significant challenge to their established franchises. With a broader serotype coverage, VAX-31 aims to address unmet needs in adult pneumococcal disease prevention, potentially capturing a substantial share of the ~$3 billion annual market. The success of these Phase 3 trials will be a key indicator of Vaxcyte’s ability to disrupt the existing landscape and establish itself as a major player.

What we're watching

Clinical Outcomes
The topline data from the OPUS-1 trial in Q4 2026 will be critical in determining whether VAX-31 demonstrates non-inferiority and superiority over existing vaccines, directly impacting its regulatory pathway.
Regulatory Risk
The FDA’s assessment of the broader dataset generated by the OPUS trials will be key, as the agency’s expectations for next-generation pneumococcal vaccines may evolve.
Market Adoption
The success of the concomitant administration study (OPUS-2) will influence Vaxcyte’s strategy for post-licensure uptake, as combined vaccination schedules are increasingly common.

Vaxcyte Data Bolsters Pneumococcal Vaccine Pipeline, Phase 3 Trial Imminent

Event summary

  • Vaxcyte published positive Phase 1/2 data for its 31-valent pneumococcal conjugate vaccine (VAX-31) in The Lancet Infectious Diseases.
  • The study, involving 1,015 adults aged 50+, demonstrated robust immune responses and a safety profile comparable to Prevnar 20.
  • Vaxcyte is advancing VAX-31 High Dose into a comprehensive Phase 3 adult program, with topline data expected in Q4 2026.
  • VAX-31 aims to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older.

The big picture

The pneumococcal vaccine market is a significant segment of the broader vaccine industry, driven by the ongoing need to combat antibiotic resistance and improve public health outcomes. Vaxcyte's VAX-31 represents a potential leap forward in coverage compared to existing vaccines, but its success hinges on demonstrating a clear clinical and economic advantage. The company's carrier-sparing platform, if validated by Phase 3 results, could establish a new standard for vaccine development, potentially impacting the entire sector.

What we're watching

Clinical Execution
The success of the OPUS Phase 3 trial is critical; failure to meet non-inferiority or superiority endpoints could significantly impact Vaxcyte’s valuation and future development plans.
Regulatory Landscape
How the FDA will weigh the incremental benefit of VAX-31 against its cost and potential for increased market penetration will be a key factor in its approval pathway.
Competitive Dynamics
The ongoing performance and strategic moves of competitors like Pfizer (Prevnar 20) and Merck (Capvaxive) will shape Vaxcyte’s ability to capture market share.

Vaxcyte Bolsters Pipeline, Manufacturing as Adult Vaccine Trials Advance

Event summary

  • Vaxcyte completed enrollment in its Phase 2 infant VAX-31 dose-finding study and initiated three Phase 3 adult clinical trials (OPUS-1, OPUS-2, and OPUS-3) for its broad-spectrum pneumococcal conjugate vaccine (PCV).
  • The company raised approximately $600 million in net proceeds from a February 2026 equity offering, bringing its total cash, cash equivalents, and investments to $2.4 billion.
  • Vaxcyte completed construction of a dedicated manufacturing facility at Lonza and initiated buildout of a fill-finish line in North Carolina to support commercialization.
  • The company plans to initiate a Phase 1 adult clinical study for VAX-A1, a vaccine candidate to prevent Group A Strep, in 2026.

The big picture

Vaxcyte is positioning itself to disrupt the established pneumococcal vaccine market, currently dominated by Pfizer and Merck, with a broader-spectrum product. The company's significant cash reserves and manufacturing investments suggest a commitment to aggressive commercialization, but success hinges on demonstrating clinical efficacy and navigating regulatory hurdles. The equity offering provides a buffer, but the company's profitability remains dependent on the successful launch and adoption of VAX-31.

What we're watching

Clinical Outcomes
The topline data from the OPUS-1 trial, expected in Q4 2026, will be critical in determining Vaxcyte’s ability to demonstrate non-inferiority compared to existing PCVs and establish a best-in-class profile, which will heavily influence future development and commercial prospects.
Manufacturing Scale
The successful and timely ramp-up of manufacturing capacity at Lonza and the North Carolina fill-finish line will be essential to meeting potential commercial demand and avoiding supply chain bottlenecks if VAX-31 receives regulatory approval.
Pipeline Diversification
The progress of VAX-A1, and its ability to move beyond the PCV franchise, will be a key indicator of Vaxcyte’s long-term growth potential and ability to mitigate risk associated with reliance on a single product.

Vaxcyte Advances Pneumococcal Vaccine Trial, Eyes 2027 Data

Event summary

  • Vaxcyte initiated the OPUS-3 Phase 3 trial evaluating VAX-31 in adults with prior pneumococcal vaccination, dosing the first participants on February 11, 2026.
  • The trial aims to assess the safety, tolerability, and immunogenicity of VAX-31, specifically its ability to boost immune responses in previously vaccinated individuals.
  • Vaxcyte anticipates topline data from the OPUS-3 and OPUS-2 trials (concomitant administration with a seasonal influenza vaccine) in the first half of 2027.
  • The Phase 3 adult clinical program for VAX-31 involves approximately 6,000 adults across three trials, with the goal of supporting a Biologics License Application (BLA) submission.
  • VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50+.

The big picture

Vaxcyte's VAX-31 represents a significant effort to address the ongoing challenge of pneumococcal disease, a major public health concern with rising antibiotic resistance. The broader coverage offered by VAX-31, potentially exceeding current standard-of-care vaccines by a substantial margin (14-34% for IPD, 19-31% for pneumonia), positions it to capture a significant share of the ~$3 billion global pneumococcal vaccine market if clinical trials prove successful. The company's reliance on its XpressCF platform for manufacturing consistency will be a key factor in scaling production and meeting potential demand.

What we're watching

Regulatory Risk
The FDA’s continued alignment with Vaxcyte’s development program will be crucial for a timely BLA submission, and any shifts in regulatory expectations could delay the process.
Competitive Landscape
The performance of VAX-31 relative to existing vaccines like Prevnar 20 and Pneumovax 23, particularly in boosting immune responses in previously vaccinated patients, will determine its market adoption.
Execution Risk
The successful enrollment and completion of the three Phase 3 trials, involving approximately 6,000 adults, within the projected timeframe will be essential for meeting the 2027 data reporting deadline.

Vaxcyte to Detail Pneumococcal Vaccine Pipeline at Guggenheim Biotech Summit

Event summary

  • Vaxcyte management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026.
  • The event will be webcast live and available for replay on Vaxcyte's investor relations website.
  • Vaxcyte is developing VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) in Phase 3 trials, and VAX-24, a 24-valent PCV in earlier development.
  • The company utilizes XpressCF®, a cell-free protein synthesis platform licensed from Sutro Biopharma, to accelerate vaccine development.

The big picture

Vaxcyte's participation in the Guggenheim summit signals an effort to bolster investor confidence as it advances its pipeline of pneumococcal vaccines. The company's strategy of developing broader-spectrum vaccines, leveraging a novel manufacturing platform, positions it to compete with established players in a multi-billion dollar market. However, the success hinges on demonstrating clinical efficacy and navigating potential manufacturing bottlenecks.

What we're watching

Clinical Execution
The success of the Phase 3 trial for VAX-31 will be critical for Vaxcyte's near-term valuation, and the summit provides an opportunity to assess management's confidence in the data.
Manufacturing Scale
The reliance on Sutro Biopharma’s XpressCF® platform introduces a dependency that could impact Vaxcyte’s ability to scale production to meet potential demand, a point likely to be scrutinized during the fireside chat.
Competitive Landscape
Given the crowded pneumococcal vaccine market, Vaxcyte will need to clearly articulate the differentiated benefits of its broader-spectrum candidates to justify premium pricing and market share gains.

Vaxcyte Raises $632.5 Million in Public Offering

Event summary

  • Vaxcyte closed a public offering of 12.65 million shares at $50 per share.
  • The offering included the full exercise of underwriters’ option for an additional 1.65 million shares.
  • The total gross proceeds from the offering were $632.5 million.
  • The shelf registration statement became automatically effective on May 24, 2024.
  • The offering was managed by a syndicate of investment banks including BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities, Mizuho, BTIG, and Needham & Company.

The big picture

Vaxcyte’s substantial capital raise provides a significant runway for its clinical programs and expansion of its vaccine pipeline. The offering demonstrates investor confidence in the company’s technology and potential to disrupt the pneumococcal vaccine market, which is a multi-billion dollar segment of the broader vaccine industry. However, the large offering also dilutes existing shareholders and increases the pressure on Vaxcyte to deliver on its ambitious development goals.

What we're watching

Capital Allocation
The company's stated use of proceeds will be critical to monitor; investors should assess whether the funds are deployed strategically to accelerate pipeline development and commercialization efforts, or if they are used for less value-accretive purposes.
Clinical Trial Progress
The success of Vaxcyte’s Phase 3 adult clinical program for VAX-31 will be a key determinant of future valuation, and any delays or setbacks could significantly impact investor sentiment.
Competition
The competitive landscape for pneumococcal vaccines remains intense, and Vaxcyte’s ability to differentiate its offerings and capture market share will depend on demonstrating superior efficacy and safety profiles compared to existing products.

Vaxcyte Launches $500 Million Stock Offering to Fuel Pipeline

Event summary

  • Vaxcyte initiated a public offering of $500 million in common stock and pre-funded warrants.
  • The offering includes a potential additional sale of $75 million in stock, at the underwriters’ discretion.
  • The shelf registration statement became automatically effective on May 24, 2024.
  • The offering is being managed by BofA Securities, Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities.
  • Vaxcyte utilizes the XpressCF® cell-free protein synthesis platform licensed from Sutro Biopharma.

The big picture

Vaxcyte's significant capital raise underscores the substantial investment required to advance vaccine development programs, particularly those targeting complex bacterial diseases. The offering provides a financial runway to support late-stage clinical trials for VAX-31 and further development of its pipeline, but also signals a need for external funding given the high burn rate typical of clinical-stage biopharma companies. The involvement of major investment banks suggests a degree of institutional support for Vaxcyte's long-term prospects.

What we're watching

Capital Allocation
The specific allocation of proceeds will be crucial; investors should monitor whether funds are directed towards clinical trials, manufacturing scale-up, or potential acquisitions, and whether this aligns with stated strategic priorities.
Market Reception
The success of the offering and the subsequent stock performance will reflect investor confidence in Vaxcyte’s pipeline and its ability to compete in the crowded pneumococcal vaccine market.
Dilution Impact
The introduction of pre-funded warrants will dilute existing shareholders; the long-term impact on earnings per share and valuation warrants close observation.
CID: 548